Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 18/20 | 1.00 |
| ▸ | RXRB | P28702 | 10/20 | 0.68 |
| ▸ | RXRG | P48443 | 10/20 | 0.68 |
| ▸ | RARB | P10826 | 4/20 | 0.63 |
| ▸ | RARG | P13631 | 4/20 | 0.63 |
| ▸ | RARA | P10276 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.60 |
| ▸ | ESR1 | P03372 | 1/20 | 0.60 |
| ▸ | PGR | P06401 | 1/20 | 0.60 |
| ▸ | HTR1A | P08908 | 1/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.60 |
| ▸ | DRD1 | P21728 | 1/20 | 0.60 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6907114 | 0.86 | RXRA (0.76) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL9868375 | 0.84 | RXRA (0.73) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL6822271 | 0.84 | RXRA (0.73) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL7721760 | 0.83 | RXRA (0.71) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL7720651 | 0.82 | RXRA (0.70) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL7720657 | 0.81 | RXRA (1.00) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL9271780 | 0.80 | RXRA (0.66) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL9551746 | 0.79 | RXRA (0.70) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL726140 | 0.78 | RXRA (1.00) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL30054740 | 0.78 | RXRA (1.00) | RXRARXRBRXRGRARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6391287-B1 | STORAGE STABLE COMPOSITIONS | L'OREAL (FR) | 2002-05-21 | — | — | US | claimed |
| EP-1019049-A1 | METHODS AND COMPOSITIONS FOR TREATING AND/OR PREVENTING NON-INSULIN DEPENDENT DIABETES MELLITUS (NIDDM) USING SPECIFIC RETINOID COMPOUNDS | Galderma Research & Development, S.N.C. (FR) | 2000-07-19 | — | — | EP | claimed |
| WO-1998042340-A9 | RETINOID RELATED MOLECULES FOR THE TREATMENT OF NON-INSULIN DEPENDENT DIABETES MELLITUS | — | 1999-03-04 | — | — | WO | claimed |
| WO-1998042340-A1 | RETINOID RELATED MOLECULES FOR THE TREATMENT OF NON-INSULIN DEPENDENT DIABETES MELLITUS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 1998-10-01 | — | — | WO | claimed |
| US-5766610-A | USEFUL FOR TREATMENT OF MAMMALIAN SKIN AND HAIR, RHEUMATISM, RESIPIRATORY SYSTEM DISORDER, CARDIOVASCULAR AND VISION DISORDERS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1998-06-16 | — | — | US | claimed |
| EP-0679630-B1 | Bicyclic aromatic compounds, pharmaceutical and cosmetic compositions containing them and uses | CIRD GALDERMA (FR) | 1998-05-06 | — | — | EP | claimed |
| US-20040162354-A1 | Treatment of disease states which result from neoplastic cell proliferation using PPAR-gamma activators and compositions useful therefor | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2004-08-19 | — | — | US | disclosed |
| US-6646008-B1 | Administering peroxisome proliferator activated receptor(PPAR) and retinoid acid receptor agonists such as 6-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopropyl) nicotinic acid, for prophylaxis of tumors | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2003-11-11 | — | — | US | disclosed |
| US-6586455-B1 | Administering retinoid and peroxisome proliferator-activated receptors to improve cell proliferation and differentiation of adipocytes; prophylaxis of cancer | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2003-07-01 | — | — | US | disclosed |
| US-6391287-B1 | STORAGE STABLE COMPOSITIONS | L'OREAL (FR) | 2002-05-21 | — | — | US | disclosed |
| US-6162815-A | RXR-agonist polycyclic aromatic compounds, pharmaceutical/cosmetic compositions comprising said compound and uses thereof | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2000-12-19 | — | — | US | disclosed |
| JP-2000344644-A | COMPOSITION COMPRISING AT LEAST ONE BICYCLIC AROMATIC COMPOUND AND AT LEAST ONE LIPOPHILIC SUNSCREENING AGENT, AND USE OF THE COMPOSITION | L'OREAL SA | 2000-12-12 | — | — | JP | disclosed |
| US-6156788-A | Polycyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2000-12-05 | — | — | US | disclosed |
| EP-1019049-A1 | METHODS AND COMPOSITIONS FOR TREATING AND/OR PREVENTING NON-INSULIN DEPENDENT DIABETES MELLITUS (NIDDM) USING SPECIFIC RETINOID COMPOUNDS | Galderma Research & Development, S.N.C. (FR) | 2000-07-19 | — | — | EP | disclosed |
| US-6015569-A | PYRIDINE OR PYRROLE DERIVATIVES OF POLYCYCLIC AROMATICS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2000-01-18 | — | — | US | disclosed |
| WO-1998042340-A9 | RETINOID RELATED MOLECULES FOR THE TREATMENT OF NON-INSULIN DEPENDENT DIABETES MELLITUS | — | 1999-03-04 | — | — | WO | disclosed |
| WO-1998042340-A1 | RETINOID RELATED MOLECULES FOR THE TREATMENT OF NON-INSULIN DEPENDENT DIABETES MELLITUS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 1998-10-01 | — | — | WO | disclosed |
| US-5766610-A | USEFUL FOR TREATMENT OF MAMMALIAN SKIN AND HAIR, RHEUMATISM, RESIPIRATORY SYSTEM DISORDER, CARDIOVASCULAR AND VISION DISORDERS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1998-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162354-A1 | Treatment of disease states which result from neoplastic cell proliferation using PPAR-gamma activators and compositions useful therefor | PPARA, PPARG, PPARD | RXRA 6/4885RXRB 5/4885RXRG 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.